The Short List: Current Top 10 Most Shorted Stocks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2025
0mins
Should l Buy NTLA?
Source: Benzinga
Reasons for Short Selling: Traders short stocks to either bet on a decline in value or to profit from potential short squeezes, where rising prices force short sellers to buy back shares, creating a feedback loop of increasing demand.
Characteristics of Heavily Shorted Stocks: Stocks become heavily shorted when experienced traders believe they are overvalued, indicating serious risks, while retail traders may see high short interest as an opportunity for quick gains.
Top Heavily Shorted Stocks: As of November 26, 2025, the most shorted stocks include The Wendy's Co. (WEN) at 55.36% short interest, followed by Cambium Networks Corp. (CMBM) and Lucid Group, Inc. (LCID).
Risks and Volatility: While short squeezes can lead to significant gains, they come with high risks and volatility, necessitating careful monitoring and due diligence by traders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 11.650
Low
4.00
Averages
16.50
High
54.00
Current: 11.650
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase 3 development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Therapeutics Overcomes Regulatory Setback
- Clinical Study Resumption: The FDA has lifted the clinical hold on Intellia Therapeutics' nex-z drug, allowing it to proceed with Phase 3 studies, a development that could drive stock recovery despite last year's price drop due to a patient death incident.
- Drug Potential Analysis: As a treatment for transthyretin amyloidosis, nex-z is expected to offer a one-time solution for hundreds of thousands of patients worldwide, and successful commercialization could significantly enhance Intellia's market position in the biotech sector.
- Risk Management Measures: The company plans to exclude patients with liver issues in late-stage studies of nex-z and will closely monitor liver inflammation, yet potential safety concerns may still hinder market acceptance.
- Market Competitive Landscape: While Intellia's partnership with Regeneron provides technical support, the high costs and complexities of gene editing drugs remain major barriers to commercialization, prompting investors to carefully assess future performance.
See More
Analysis of Intellia Therapeutics' Stock Price Recovery
- Stock Recovery: Intellia Therapeutics' stock has surged 47% over the past year, rebounding to $13.41 per share, reflecting increased market confidence in its innovative potential and future growth prospects.
- Clinical Progress: The FDA has lifted clinical holds on nex-z, allowing Intellia to advance its treatments for transthyretin amyloidosis and hereditary angioedema, marking a significant step in addressing previous setbacks.
- Risk Warning: Despite positive developments, the unclear causal relationship between nex-z and a patient's death raises concerns about potential future challenges in clinical trials, increasing investor apprehension.
- Market Potential: As a one-time treatment option, nex-z targets hundreds of thousands of patients with transthyretin amyloidosis globally, which could significantly reshape the market landscape if successfully launched, though high R&D costs and complex administration remain major hurdles.
See More
Cathie Wood's Intellia Therapeutics Surges 47%: Is It Too Late to Invest?
- Stock Performance: Intellia Therapeutics has seen a 47% increase in its stock price this year, reflecting strong market confidence in its gene-editing drugs, particularly after the FDA lifted clinical holds on nex-z, leading investors to be optimistic about its future prospects.
- Clinical Progress: The FDA's lifting of clinical holds on nex-z allows Intellia to advance its treatment for hereditary angioedema, a development that not only helps restore investor confidence but also has the potential to generate new revenue streams for the company.
- Risk Factors: Despite the positive developments, Intellia faces potential safety concerns, especially since the causal relationship between nex-z and a patient's death remains unclear, which could complicate future clinical trials and increase investment uncertainty.
- Market Competition: Intellia's partnership with Regeneron provides robust support for the development of nex-z, yet the high costs and complexities associated with gene-editing drugs remain significant barriers to market adoption, potentially limiting its acceptance among third-party payers.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perceptions of these firms.
- Market Focus: Analysts' views on TGT stock have garnered investor attention, indicating differing expectations for its future performance, which could influence investment decisions.
- Impact of Rating Changes: Changes in ratings may affect investor confidence, directly impacting trading volumes and price fluctuations of TGT stock, especially amid increasing market uncertainty.
- Access More Information: Investors can visit the analyst ratings page to view a complete overview of all rating changes, enabling more informed investment decisions.
See More
Wall Street Analysts Adjust GE Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on General Electric (GE) stock, indicating a shift in market sentiment, although specific rating changes were not detailed in the report.
- Market Reaction Insight: While specific upgrades or downgrades were not provided, the change in analysts' perspectives could influence investor decisions, particularly among those considering purchasing GE stock.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in market dynamics, and investors should pay attention to these changes to make informed investment choices.
- Overall Market Trends: Changes in analyst ratings often signal market expectations regarding a company's future performance, thus investors should closely monitor these updates to seize potential investment opportunities.
See More
Intellia Presents New Research at AAAAI Meeting
- Clinical Trial Results: In a pooled Phase 1/2 analysis involving 32 hereditary angioedema (HAE) patients, a single 50 mg dose of lonvo-z resulted in a mean monthly attack rate of ≤0.2, representing a 96% reduction from baseline, highlighting the potential long-term safety and efficacy of lonvo-z.
- Evolving Treatment Goals: Among 28 patients who received lonvo-z, 86% achieved attack-free and long-term prophylaxis-free status after more than six months of follow-up, indicating a strong alignment between patient needs for reduced treatment burden and clinical objectives.
- Biological Modeling Study: Research indicates that significant C1-esterase inhibitor deficiency in HAE patients leads to excessive plasma kallikrein generation, with models showing that an 85% reduction in prekallikrein can normalize kallikrein and bradykinin levels, supporting the clinical efficacy of lonvo-z.
- Patient Challenge Survey: A survey of 100 HAE patients revealed that 34% experienced at least one attack per month, with only 20% being attack-free in the past year, underscoring the demand for lonvo-z as patients seek to eliminate chronic medication use to improve treatment outcomes.
See More
Intellia Therapeutics Overcomes Regulatory Setback
- Clinical Study Resumption: The FDA has lifted the clinical hold on Intellia Therapeutics' nex-z drug, allowing it to proceed with Phase 3 studies, a development that could drive stock recovery despite last year's price drop due to a patient death incident.
- Drug Potential Analysis: As a treatment for transthyretin amyloidosis, nex-z is expected to offer a one-time solution for hundreds of thousands of patients worldwide, and successful commercialization could significantly enhance Intellia's market position in the biotech sector.
- Risk Management Measures: The company plans to exclude patients with liver issues in late-stage studies of nex-z and will closely monitor liver inflammation, yet potential safety concerns may still hinder market acceptance.
- Market Competitive Landscape: While Intellia's partnership with Regeneron provides technical support, the high costs and complexities of gene editing drugs remain major barriers to commercialization, prompting investors to carefully assess future performance.
See More
Analysis of Intellia Therapeutics' Stock Price Recovery
- Stock Recovery: Intellia Therapeutics' stock has surged 47% over the past year, rebounding to $13.41 per share, reflecting increased market confidence in its innovative potential and future growth prospects.
- Clinical Progress: The FDA has lifted clinical holds on nex-z, allowing Intellia to advance its treatments for transthyretin amyloidosis and hereditary angioedema, marking a significant step in addressing previous setbacks.
- Risk Warning: Despite positive developments, the unclear causal relationship between nex-z and a patient's death raises concerns about potential future challenges in clinical trials, increasing investor apprehension.
- Market Potential: As a one-time treatment option, nex-z targets hundreds of thousands of patients with transthyretin amyloidosis globally, which could significantly reshape the market landscape if successfully launched, though high R&D costs and complex administration remain major hurdles.
See More
Cathie Wood's Intellia Therapeutics Surges 47%: Is It Too Late to Invest?
- Stock Performance: Intellia Therapeutics has seen a 47% increase in its stock price this year, reflecting strong market confidence in its gene-editing drugs, particularly after the FDA lifted clinical holds on nex-z, leading investors to be optimistic about its future prospects.
- Clinical Progress: The FDA's lifting of clinical holds on nex-z allows Intellia to advance its treatment for hereditary angioedema, a development that not only helps restore investor confidence but also has the potential to generate new revenue streams for the company.
- Risk Factors: Despite the positive developments, Intellia faces potential safety concerns, especially since the causal relationship between nex-z and a patient's death remains unclear, which could complicate future clinical trials and increase investment uncertainty.
- Market Competition: Intellia's partnership with Regeneron provides robust support for the development of nex-z, yet the high costs and complexities associated with gene-editing drugs remain significant barriers to market adoption, potentially limiting its acceptance among third-party payers.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perceptions of these firms.
- Market Focus: Analysts' views on TGT stock have garnered investor attention, indicating differing expectations for its future performance, which could influence investment decisions.
- Impact of Rating Changes: Changes in ratings may affect investor confidence, directly impacting trading volumes and price fluctuations of TGT stock, especially amid increasing market uncertainty.
- Access More Information: Investors can visit the analyst ratings page to view a complete overview of all rating changes, enabling more informed investment decisions.
See More
Wall Street Analysts Adjust GE Stock Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on General Electric (GE) stock, indicating a shift in market sentiment, although specific rating changes were not detailed in the report.
- Market Reaction Insight: While specific upgrades or downgrades were not provided, the change in analysts' perspectives could influence investor decisions, particularly among those considering purchasing GE stock.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in market dynamics, and investors should pay attention to these changes to make informed investment choices.
- Overall Market Trends: Changes in analyst ratings often signal market expectations regarding a company's future performance, thus investors should closely monitor these updates to seize potential investment opportunities.
See More
Intellia Presents New Research at AAAAI Meeting
- Clinical Trial Results: In a pooled Phase 1/2 analysis involving 32 hereditary angioedema (HAE) patients, a single 50 mg dose of lonvo-z resulted in a mean monthly attack rate of ≤0.2, representing a 96% reduction from baseline, highlighting the potential long-term safety and efficacy of lonvo-z.
- Evolving Treatment Goals: Among 28 patients who received lonvo-z, 86% achieved attack-free and long-term prophylaxis-free status after more than six months of follow-up, indicating a strong alignment between patient needs for reduced treatment burden and clinical objectives.
- Biological Modeling Study: Research indicates that significant C1-esterase inhibitor deficiency in HAE patients leads to excessive plasma kallikrein generation, with models showing that an 85% reduction in prekallikrein can normalize kallikrein and bradykinin levels, supporting the clinical efficacy of lonvo-z.
- Patient Challenge Survey: A survey of 100 HAE patients revealed that 34% experienced at least one attack per month, with only 20% being attack-free in the past year, underscoring the demand for lonvo-z as patients seek to eliminate chronic medication use to improve treatment outcomes.
See More
